Table 1 Baseline clinical characterics of the study population.
| Â | IHD1 (n = 40) | IHD 2 (n = 40) | IHD 3 (n = 40) | P | Control Group (n = 40) |
|---|---|---|---|---|---|
Age | 60 ± 15 | 60 ± 11 | 64 ± 15 | NS | 64 ± 10 |
Male | 24 | 26 | 25 | NS | 21 |
Cardiovascular Risk Factors % (n) | Â | Â | Â | Â | Â |
   Hypertension | 80 (n = 32) | 80 (n = 32) | 78 (n = 31) | NS | - |
   Hyperlipidemia | 60 (n = 24) | 60 (n = 24) | 53 (n = 21) | NS | - |
   Smoking | 68 (n = 27) | 75 (n = 30) | 63 (n = 25) | NS | - |
   Positive family history of CAD | 40 (16) | 40 (n = 16) | 35 (n = 14) | NS | - |
   Diabetes | 20 (n = 8) | 20 (n = 8) | 60 (n = 24) | p = 0.001 | - |
OHA | 15 (n = 6) | 15 (n = 6) | 45 (n = 18) | NS | - |
Insulin | 5 (n = 2) | 5 (n = 2) | 15 (n = 6) | NS | - |
Total number of CVRFs | 4.2 ± 0.8 | 4.3 ± 0.8 | 4.4 ± 0.9 | NS | - |
Infarct-related vessel (LAD/LCX/RCA) | 19/8/13 | 20/10/11 | 20/8/12 | NS | - |
PTCA/Stent at the time of AMI | 40/40 | 40/40 | 40/40 | NS | - |
Ejection fraction (%) | 45 ± 10 | 43 ± 11 | 40 ± 10 | NS | 69 ± 9 |
Medication (%) | Â | Â | Â | Â | - |
   Aspirin | 100 | 100 | 100 | NS | - |
   Clopidogrel | 100 | 100 | 100 | NS | - |
   ACE inhibitor or AT II blocker | 100 | 100 | 100 | NS | - |
   Beta-blocker | 100 | 100 | 100 | NS | - |
   Aldosterone Antagonist | 25 | 25 | 30 | NS | - |
   Statin | 100 | 100 | 100 | NS | - |